3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells
1997

Astatine-211-labeled Fluorobenzylguanidine for Neuroblastoma Treatment

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): G Vaidyanathan, X-G Zhao, RH Larsen, MR Zalutsky

Primary Institution: Duke University Medical Center

Hypothesis

Can the astatine-211-labeled analogue of fluorobenzylguanidine improve retention in neuroblastoma cells compared to its iodine-labeled counterpart?

Conclusion

The study found that the astatine-211-labeled fluorobenzylguanidine has higher retention in neuroblastoma cells compared to the iodine-labeled version.

Supporting Evidence

  • The uptake of [211At]AFBG was significantly higher than that of [131I]MIBG in neuroblastoma cells.
  • Retention of [211At]AFBG in normal tissues was also evaluated, showing promising results.
  • Statistical analysis indicated significant differences in retention rates between the compounds.

Takeaway

Researchers are testing a new treatment for a type of cancer called neuroblastoma, using a special substance that sticks better to cancer cells than older treatments.

Methodology

The study evaluated the in vitro and in vivo properties of the new compound by measuring its uptake and retention in human neuroblastoma cells and normal mouse tissues.

Limitations

The study primarily focused on in vitro and initial in vivo evaluations, which may not fully represent clinical outcomes.

Participant Demographics

Male BALB/c mice weighing about 25 g were used for the in vivo experiments.

Statistical Information

P-Value

< 0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication